Brief Article
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2012; 18(1): 49-54
Published online Jan 7, 2012. doi: 10.3748/wjg.v18.i1.49
Outcome after gastrectomy in gastric cancer patients with type 2 diabetes
Jong Won Kim, Jae-Ho Cheong, Woo Jin Hyung, Seung-Ho Choi, Sung Hoon Noh
Jong Won Kim, Seung-Ho Choi, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, South Korea
Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Choi SH and Noh SH designed the research; Kim JW, Cheong JH, Hyung WJ, Choi SH, and Noh SH performed the research; Kim JW, Cheong JH, and Hyung WJ analyzed the data; and Kim JW and Choi SH wrote the paper.
Correspondence to: Seung-Ho Choi, MD, PhD, Professor of Medicine, Chief of Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 712 Eonjuro, Gangnam-gu, Seoul 135-720, South Korea.
Telephone: +82-2-20193373 Fax: +82-2-34625994
Received: March 17, 2011
Revised: April 15, 2011
Accepted: April 22, 2011
Published online: January 7, 2012

AIM: To evaluate the prognosis of type II diabetes mellitus (T2DM) after gastrectomy and related factors in gastric cancer patients.

METHODS: 403 gastric cancer patients with T2DM were studied, who underwent gastrectomy between May 2003 and September 2009. A review of medical records and telephone interviews was performed in this cross-sectional study. The factors included in the statistical analysis were as follows: gender, age, type of surgery, preoperative body mass index (BMI), current BMI, BMI reduction ratio, preoperative insulin or oral diabetic medicine requirement, follow-up duration, and current state of diabetes. Assessment of diabetes status after surgery was classified into four categories according to the change in hypoglycemic agents after surgery and present status of T2DM: resolution, improvement, same, and worse.

RESULTS: The mean follow-up duration was 33.7 mo (± 20.6 mo), preoperative BMI was 24.7 kg/m2 (± 3.0 kg/m2), and BMI reduction ratio was 9.8% (± 8.6%). After surgery, T2DM was cured in 58 patients (15.1%) and was improved in 117 patients (30.4%). According to the type of surgery, the BMI reduction ratio was significantly higher in the total gastrectomy and Roux-en-Y reconstruction group [14.2% ± 9.2% vs 9.2% ± 7.7% (Billroth II group), P < 0.001] and significantly lower in the subtotal gastrectomy and Billroth I reconstruction group [7.6% ± 8.0%, 9.2% ± 7.7% (Billroth II group), P < 0.001]. The BMI reduction ratio, follow-up duration after surgery, type of surgery, extent of gastrectomy, and performance of duodenal bypass were significantly correlated to the course of T2DM (P < 0.05). The BMI reduction ratio was the most influential factor on T2DM status. In a subgroup analysis of patients with a BMI reduction ratio of 10% or less (n = 206), T2DM was cured in 15 (7.6%) patients and was improved in 57 (28.8%) patients after surgery, and only the duration of surgery was significantly correlated to T2DM status (P = 0.022).

CONCLUSION: The course of T2DM was significantly correlated to the BMI reduction ratio but not to the type of surgery without a significant change in BMI.

Keywords: Gastric cancer, Diabetes mellitus, Metabolic surgery, Bariatric surgery